Clinical Study of Chronic Graft-Versus-host Disease after Allogeneic Hematopoietic Stem Cell Transplantation
夏凌辉,邹萍,胡俊斌,游泳,方峻,郭涛,刘芳,张纯,崔国惠,谢薇,宋善俊
DOI: https://doi.org/10.3760/cma.j.issn.0254-1785.2007.07.012
2007-01-01
Abstract:Objective To investigate the clinical characteristics,associated risk factors and therapeutic effectiveness of chronic graft-versus-host disease(cGVHD)after allogeneic hematopoietic stem cell transplantation(allo-HSCT).Methods The clinical data of cGVHD were retrospectively analyzed from 69 patients who underwent alIo-HSCT.All patients were divided into three groups according to the relation between donor and recipient and HLA matching:22 patients of sibling- matched bone marrow transplantation in group A;37 patients of sibling-matched peripheral blood stem cell transplantation in group B;10 patients of matched unrelated donor HSCT or sibling-mismatched HSCT in group C.All of them were subjected to chemotherapy for preconditioning before transplanta- tion,and short-term methoterexate(MTX)combined with cyclosporine(CsA)for GVHD prophylaxis after transplantation.Patients with limited cGVHD were usually treated with immunosuppressive agent(CsA or glucocorticoid)alone,and those with advanced condition were administrated with stan- dard regimen(CsA combined with glucocorticoid);while those with extensive cGVHD were treated with standard regimen(first line therapy).Those who were not responsive to first line therapy and had a progressive disease condition,or those who were refractory to the first line therapy and relapsed when drug withdrawal were treated with tacrolimus,mycophenolate and azathioprine(second line therapy).Results During a median follow-up period of 43 months(6-120 months),39 patients deve- loped cGVHD after transplantation.Limited cGVHD developed in 13 of 39 patients(33.3%),while extensive cGVHD developed in 26 of 39 patients(66.7%).Seven died of cGVHD or related compli- cations,cGVHD incidence in group B was much higher than in group A(P0.05),while incidence of extensive cGVHD in groups B and C were much higher than in group A(P0,05).Peripheral blood stem cell transplant and development of gradeⅡ-Ⅳacute GVHD were the independent risk factors of cGVHD.It was also proven that patients with limited eGVHD who treated with first line therapy had a better therapeutic effect than those with extensive cGVHD(P0.05);therapeutic effectiveness of first line therapy for cGVHD in standard risk group was much better than that in high risk group(P0.05).Conclusion cGVHD is the common complication and reasons of causing death in later period after allo-HSCT.Clinically extensive cGVHD usually develops in patients undergoing allo-PBSCT, HLA mismatched HSCT and MUD-HSCT,and has a worse clinical therapeutic effect.